Influence of rosuvastain on the lipid profile and inflammatory markers in patients with gout and arterial hypertension by Zolotariova, N. A. & Romanchenko, M. I.
  
627 
Zolotariova N. A., Romanchenko M. I. Influence of rosuvastain on the lipid profile and inflammatory markers in patients with gout 







The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26.01.2017). 
1223 Journal of Education, Health and Sport eISSN 2391-8306 7 
© The Authors 2017; 
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland 
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,  
provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribut ion Non Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
This is an open access article licensed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted, non commercial 
use, distribution and reproduction in any medium, provided the work is properly cited.  
The authors declare that there is no conflict of interests regarding the publication of this paper.  
Received: 15.08.2017. Revised: 20.09.2017. Accepted: 29.09.2017. 
 
INFLUENCE OF ROSUVASTAIN ON THE LIPID PROFILE AND 
INFLAMMATORY MARKERS IN PATIENTS WITH GOUT AND ARTERIAL 
HYPERTENSION 
N. A. Zolotariova, M. I. Romanchenko 
 
Odessa National Medical University, Odessa, Ukraine 
 
Abstract 
Currently there is scarce data on lipid-lowering effects of rosuvastatin in 
rheumatologic pathology, moreover there are no current studies of its anti-inflammatory 
activity in patients with gout comorbid with arterial hypertension (AH). The purpose of this 
study is to investigate the lipid-lowering and anti-inflammatory effect of combination therapy 
with the addition of rosuvastatin in patients with gout AH. We measured and compared the 
level of total cholesterol, TG, LDL, VLDL, HDL, atherogenic index (AI) as well as 
biochemical parameters of inflammation (ESR, C-reactive protein, sialic acids, seromucoid 
and fibrinogen-A in 30 patients (29 male, 1 female) with gout + AH, the observation period 
was 43 ± 9 days. The study showed decrease in total cholesterol by 29,2% to 3,88 ± 0,78 
mmol/L (p<0,0001), decrease in triglycerides by 23,91% to 1,40 [1,12 – 1,94] mmol/L 
(p=0,01), LDL decrease by 36,95% to 1,86 ± 0,51 mmol/L (p<0,0001), normalizing in 
86,67% of patients, no effect on HDL, remaining at a level of 1,23 mmol/L and significant 
normalization of atherigenic index decreasing to 2,23 ± 0,83 (-30,53%, p<0,0001). 
Inflammation markers showed significant positive dynamics: ESR significantly decreased to 
15,90 ± 9,33 mm/h (p <0,0001), the level of C-RP reached a normal value of 1,34 [0 – 6,0] 
mg/ml (p = 0,0007), and the concentration of sialic acid and seromucoid decreased and 
reached the upper limit of the norm (202,33 ± 44,0 at p=0,07 and 5,0 ± 1,25 U at p=0,004 
respectively). This study shows that standard therapeutic complex with the addition of 
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rosuvastatin at a dose of 10 mg/day leads to a statistically significant normalization of the 
average levels of total cholesterol, triglycerides, LDL and VLDL and atherogenic index, 
causing no effect on the level of HDL. Additionally this treatment leads to significant 
normalization of the levels of C-RP, seromucoid and sialic acids, as well as statistically 
significant, but not reaching the normal values reduction of ESR and fibrinogen-A, indicating 
the anti-inflammatory effect of this therapeutic complex. 
Keywords: hypertension, gout, lipid profile, inflammation, rosuvastatin 
 
Introduction 
Research on the possibility of using statins in systemic rheumatic diseases began in the 
2000s, but quite a few of investigations are devoted to the effects of rosuvastatin in 
rheumatologic pathology [1, 7, 11]. Also, only a few papers describe pleiotropic effects of 
rosuvastatin, and data on the effectiveness of this drug in patients with gout with arterial 
hypertension (AH) are absent. At the same time, the literature presents data on anti-
inflammatory [8, 13] and the possible anticoagulant [9, 10] effect of statins, which causes a 
considerable interest in the study of these effects in patients with gout, comorbid with 
hypertension. 
Statins are long-proven leaders in their lipid-correcting effect and are currently part of 
the protocol therapy according to European and National guidelines for the treatment of 
coronary artery disease [12]. At the same time, it is recommended to use the maximum high 
doses of drugs, and only in the case of their intolerance or at a low risk of cardiovascular 
complications - the average therapeutic, for which, it should be noted, regression of 
atherosclerotic plaque is not proven, but its stabilization is confirmed [13]. Despite its greatest 
influence on the main atherogenic fractions (total cholesterol, LDL, VLDL), the effects of 
different statins are slightly different from each other. Thus, in the REVERSAL study (1999-
2003) [4], the use of the maximum dose of atorvastatin (80 mg/day) led to lowering of LDL 
by 46,3% with an insignificant increase in HDL, resulting in a significant decrease in 
atherosclerotic plaque after 18 months of treatment by 0,4%. Interestingly, pravastatin use at a 
dose of 40 mg/day was accompanied by a further increase in atherosclerotic plaque (+ 2,4%), 
despite of 25,2% reduction in LDL. The ASTEROID study was also mainly aimed at 
regression of coronary atherosclerosis by taking maximal doses of rosuvastatin (40 mg/day) 
for 2 years. Intravascular ultrasound showed a significant decrease in the amount of 
atherosclerotic plaque by 1% compared toinitial values, a decrease in LDL by 53,2% and an 
increase in HDL by 14,7% [5]. However, the described effect of increasing HDL while taking 
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rosuvastatin is not present in all studies. A study by R. Rawlings et al. showed that taking 10 
mg/day of rosuvastatin for 8 weeks did not lead to a significant increase in HDL [8]. 
In the SATURN study [3], a direct comparison was made between administration of 
high doses of rosuvastatin (40 mg/day) and atorvastatin (80 mg/day) in patients with coronary 
artery disease, which showed a more pronounced regression of atherosclerotic plaques in the 
rosuvastatin group (-1,22 %) against atorvastatin (-0,99%). Also, rosuvastatin caused a 
decrease in LDL by 48% and atorvastatin by 41%. 
The efficacy of rosuvastatin as a possible hypolipidemic agent for the treatment of 
patients with gout comorbid with hypertension is of particular interest because the risk of 
atherosclerosis in these patients is extremely high [2], however, data on the lipid profile in 
patients with gout with concomitant arterial hypertension were not found in the literature. 
A number of studies have shown the presence of a lipid-independent anti-
inflammatory statin therapy effect associated with the ability of this group of drugs to block 
the prenylation of a large number of cytokines and other intercellular molecules, thereby 
inhibiting the Rho-kinase enzyme and stabilizing eNOS mRNA [8]. This, in turn, leads to a 
decrease in the proliferation of lymphocytes and their adhesion to the vascular wall, slowing 
the aging of endothelial cells by enhancing the expression of eNOS, SIRT1 and catalase [6], 
increasing the migration of nutrients and energy in the presence of sufficient amounts of 
mevalonateand, accordingly, improvement of the function of the endothelium. Thus, the data 
obtained convincingly prove that the most powerful and significant is the lipid-lowering effect 
of statin therapy, but in addition to it, biochemical mechanisms have been observed in 
experimental studies, which are now considered as the cause of the so-called pleiotropic 
effects of this group of drugs. 
The purpose of the study is to study the lipid-lowering and anti-inflammatory effect 
of combination therapy with the addition of rosuvastatin in patients with gout and 
concomitant arterial hypertension. 
Materials and methods 
The study included 30 patients with gout with arterial hypertension. The average age 
of patients was 58,0 [48,0 – 72,0] years, the group included 29 men and 1 woman.All patients 
received standard therapy for gout and arterial hypertension, additionally receiving 10 mg of 
rosuvastatin per day. The observation period was 43 ± 9 days. 
The study of lipid profile (total cholesterol, TG, LDL, HDL) was performed on an 
automatic biochemical analyzer Cobas Mira Plus (Switzerland) using "VIOLABTEST" 
(Czech Republic) reagent kits. Other indicators (VLDL, AI) were determined by the 
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calculation method. For the study of biochemical parameters of inflammation (ESR, C-
reactive protein, sialic acids, seromucoid and fibrinogen-A), common methods recommended 
by the Ministry of Health of Ukraine for use in wide clinical practice were used. Biochemical 
testswere carried out at the beginning and at the end of the observation period. 
The results of descriptive statistics are presented as mean ± standard deviation (for 
data with a normal distribution), and the median [25 - 75 quartiles] (for data with a 
distribution different from the normal). Testing of all samples for normality was done using 
the Shapiro-Wilk test. To determine the reliability of the differences between bounded 
samples with normal distribution and with similar dispersions, parametric methods were used 
(t-test), in the case of a distribution other than normal, a non-parametric Wilcoxon test was 
used. A value of p≤0,05 was considered statistically significant. 
Results and discussion 
As can be seen from Table 1, patients of the study group were characterized by an 
increase in total cholesterol (5,48 ± 1,00 mmol/L) and its proatherogenic fractions - TG (1,84 
[1,40 – 2,31] mmol/L), LDL (2,95 ± 0,66 mmol/L) and VLDL cholesterol (0,86 [0,60 – 1,04] 
mmol/L), as well as decreased levels of HDL (1,23 [1,02 – 1,45] mmol/L). As a result, the 
atherogenic index was higher than normal and was 3,21 ± 1,13. 
Table 1 
Indicators of lipid metabolism in patients with gout and arterial hypertension before and after 

















1,84 [1,40 – 
2,31] 
1,40 [1,12 – 
1,94] 
-23,91 0,01 
β-lipoproteins, U < 2,5 58,45 ± 17,96 45,03 ± 12,84 -22,96 <0,0001 
HDL, mmol/L 
< 0,8 
1,23 [1,02 – 
1,45] 
1,23 [1,02 – 
1,38] 
0,00 0,54 
LDL, mmol/L <45 2,95 ± 0,66 1,86 ± 0,51 -36,95 <0,0001 
VLDL, mmol/L 
> 1,5 
0,86 [0,60 – 
1,04] 





< 3,0 3,21 ± 1,13 2,23 ± 0,83 -30,53 <0,0001 
 
It can be seen that protocol therapy with the addition of rosuvastatin (10 mg/day), led 
to the most pronounced decrease in proatherogenic fractions of cholesterol (LDL, TG and 
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VLDL) and total cholesterol, and the level of HDL remained unchanged. The dynamics of 
these indicators in the treatment process is also presented in Fig. 1. 
 
 
Figure 1. Dynamics of atherogenic lipid fractions after using complex therapy with 
rosuvastatin in patients with gout and hypertension 
 
As seen from Figure 1, treatment with rosuvastatin resulted in a decrease in total 
cholesterol by 29,2% to 3,88 ± 0,78 mmol/L (p<0,0001), which corresponds to the normal 
level achieved at the end of the observation at 56, 67% of patients (n = 17). Earlier in the 
ASTEROID study, a more pronounced effect of rosuvastatin was observed, with a decrease in 
cholesterol by 33,8% [5], and a SATURN study showed a result of 27,98% [3] with a dose of 
40 mg/day. 
The level of triglycerides after therapy also showed a significant positive dynamics, 
dropping by 23,91% to 1,40 [1,12 – 1,94] mmol/L. In the previously noted randomized 
studies, a lower result was observed: -14,5% in the ASTEROID study and -6,25% in the 
SATURN study. As a result of treatment, normal parameters reached 63,3% of patients (n = 
19) of the study group. 
The main indicator of the proatherogenic blood potential– LDL – declinedmost 
significantly - by 36,95% to 1,86 ± 0,51 mmol/L (p<0,0001), normalizing in 86,67% of 
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patients (n = 26). The use of higher doses of rosuvastatin in randomized trials led to a 
decrease of 53,2% (ASTEROID) and 47,83% (SATURN), respectively. 
The level of anti-atherogenic HDL after rosuvastatin therapy did not improve, 
remaining at a level of 1,23 mmol/L, which is lower than normal. In the past studies patients 
with CAD showed HDL-boosting effect of rosuvastatin - in the ASTEROID study it increased 
by 14,7%, and in the SATURN study by 11,26%. However, studying the effect of a 10 
mg/day dose did not show such an effect [8], which coincides with our results. There is also 
evidence from individual authors that there is no effect of atorvastatin in a daily dose of 20 
mg on HDL [14]. 
The Atherogenity index in patients of this group showed a significant normalization 
decreasing to 2,23 ± 0,83 (p<0,0001), decreasing by 30,53%. This was the result of a 
significant reduction in the level of proatherogenic LDL in the background of unchanged 
HDL. 
Results of the study of biochemical inflammation activity indicators - ESR, C-RP, 
sialic acids, seromucoid, fibrinogen-A before and after treatment are presented in Table 2. 
Table 2 
Biochemical parameters of the patients with gout and arterial hypertension before and 
after standard therapy with rosuvastatin 





ESR, mm/h 1,0 – 10,0 21,70 ± 11,38 15,90 ± 9,33 <0,0001 
C-RP, mg/mL 0,0 – 6,0 10,5 [0 – 12,0] 1,34 [0 – 6,0] 0,0007 
Sialic acids, U 120,0 – 200,0 237,33 ± 95,66 202,33 ± 44,0 0,07 
Seromucoid, U 3,0 – 5,0 5,78 ± 1,23 5,0 ± 1,25 0,004 
Fibrinogen, g/L 2,0 – 4,0 5,66 ± 2,12 4,38 ± 1,64 0,002 
 
The results show that after standard treatment with the addition of rosuvastatin all the 
inflammatory markers showed significant positive dynamics: ESR significantly decreased to 
15,90 ± 9,33 mm/h (p <0,0001) not reaching normal levels, the level of C-RP reached a 
normal value of 1,34 [0 – 6,0] mg/ml (p = 0,0007), and the concentration of sialic acid and 
seromucoid decreased and reached the upper limit of the norm (202,33 ± 44,0 at p=0,07 and 
5,0 ± 1,25 U at p=0,004 respectively). It should be emphasized that the normal values were 
reached only by the levels of C-RP, the other markers of inflammation did not show complete 
normalization: their mean values only approached the normal range. In our opinion, this can 
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be due to the persistence of inflammatory activity of a low degree, which is 
commonforpatients with moderate and severe gout. Additionally, our observation period 
could be not long enough for complete development of anti-inflammatory effect of studied 
treatment.  
Conclusions: 
The data shows that standard therapeutic complex with the addition of rosuvastatin at 
a dose of 10 mg/day leads to a statistically significant normalization of the average levels of 
total cholesterol, triglycerides, LDL and VLDL, causing no effect on the level of HDL. 
However, atherogenic index in these patients shows significant normalization. 
Additionally, the treatment with rosuvastatin leads to significant normalization of the 
levels of C-RP, seromucoid and sialic acids, as well as statistically significant, but not 
reaching the normal values reduction of ESR and fibrinogen-A, indicating the anti-
inflammatory effect of this therapeutic complex. 
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